{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Smith GS"],"funding":["National Center for Advancing Translational Sciences","National Center for Research Resources","NCATS NIH HHS","NIA NIH HHS","NIMH NIH HHS","National Institute of Mental Health","National Institutes of Health","National Institute on Aging"],"pagination":["108447"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8716112"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["194"],"pubmed_abstract":["Patients with late-life depression (LLD) have a more variable response to pharmacotherapy relative to patients with mid-life depression. Degeneration of the serotonergic system and lower occupancy of the initial target for antidepressant medications, the serotonin transporter (5-HTT), may contribute to variability in treatment response. The focus of this study was to test the hypotheses that lower cortical and limbic serotonin transporter (5-HTT) availability in LLD patients relative to controls and less 5-HTT occupancy by antidepressant medications would be associated with less improvement in mood and cognition with treatment in LLD patients. Twenty LLD patients meeting DSM-IV criteria for a current major depressive episode and 20 non-depressed controls underwent clinical and neuropsychol"],"journal":["Neuropharmacology"],"pubmed_title":["Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression."],"pmcid":["PMC8716112"],"funding_grant_id":["MH064823","R01 AG059390","UL1 TR003098","R01 AG041633","UL1 TR001079","AG059390","R01 MH064823","AG038893","AG041633","MH086881","R01 MH086881","R01 AG038893"],"pubmed_authors":["Smith GS","Joo JH","Mathews WB","Dannals RF","Nandi A","Holt DP","Bigos KL","Kraut M","Kuwabara H","Workman CI","Hall AW","Brasic J","Savonenko A","Gould NF","Nassery N"],"additional_accession":[]},"is_claimable":false,"name":"Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.","description":"Patients with late-life depression (LLD) have a more variable response to pharmacotherapy relative to patients with mid-life depression. Degeneration of the serotonergic system and lower occupancy of the initial target for antidepressant medications, the serotonin transporter (5-HTT), may contribute to variability in treatment response. The focus of this study was to test the hypotheses that lower cortical and limbic serotonin transporter (5-HTT) availability in LLD patients relative to controls and less 5-HTT occupancy by antidepressant medications would be associated with less improvement in mood and cognition with treatment in LLD patients. Twenty LLD patients meeting DSM-IV criteria for a current major depressive episode and 20 non-depressed controls underwent clinical and neuropsychol","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-04T19:40:32.776Z","creation":"2025-04-04T19:40:32.776Z"},"accession":"S-EPMC8716112","cross_references":{"pubmed":["33450276"],"doi":["10.1016/j.neuropharm.2021.108447"]}}